Letís start with what we know. For years, the state of pharmaceutical drug development has been in decline in terms of new molecular entities or biologics that are clearing FDA approval.
Itís common knowledge that the pharmaceutical industry is in the throes of change. The blockbuster model it has relied upon for decades is no longer viable, but what will take its place? Finding a niche area, perhaps, or going after orphan drugs, or moving into emerging markets.